FDA Drug Recalls

Recalls / Class I

Class ID-1216-2015

Class I— FDA's most serious classification, issued when there is a reasonable probability that use of or exposure to the drug will cause serious adverse health consequences or death.

Product

Bupivacaine Hydrochloride Inj., USP, 0.5% (5 mg/mL), Preservative-Free, 30 mL Single Use Vials, Rx only. HOSPIRA, INC., LAKE FOREST, IL 60045 USA. NDC: 0409-1162-02.

Brand name
Bupivacaine Hydrochloride
Generic name
Bupivacaine Hydrochloride
Active ingredient
Bupivacaine Hydrochloride
Route
Epidural, Infiltration, Intracaudal, Perineural
NDCs
0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042
FDA application
ANDA070583
Affected lot / code info
Lot #: 38-515-DK, Expiry: 1 FEB 2016.

Why it was recalled

Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.

Recalling firm

Firm
Hospira Inc.
Manufacturer
Hospira, Inc.
Notification channel
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Type
Voluntary: Firm initiated
Address
600 N Field Dr, N/A, Lake Forest, Illinois 60045-4835

Distribution

Quantity
150,950 Vials
Distribution pattern
U.S. Nationwide including Guam.

Timeline

Recall initiated
2015-04-23
FDA classified
2015-07-08
Posted by FDA
2015-07-15
Terminated
2016-01-26
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1216-2015. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.